Jove
Visualize
Contáctanos

Videos de Conceptos Relacionados

Preclinical Development: Overview01:28

Preclinical Development: Overview

5.7K
Preclinical development consists of a series of tests that ensure the safety and efficacy of a new therapeutic compound before it is tested in humans. There are four main phases to this process. First, safety pharmacology tests are conducted to ensure the drug does not produce any acutely harmful effects. These tests examine parameters such as bronchoconstriction, cardiac dysrhythmias, blood pressure changes, and ataxia. Next, preliminary toxicological testing is performed to determine the...
5.7K
Clinical Trials: Overview01:11

Clinical Trials: Overview

4.5K
Clinical development focuses on how the drug will interact with the human body and encompasses four key phases of clinical trials, each serving a specific purpose in assessing the safety and effectiveness of new drugs. These phases overlap and build upon one another. Phase I involves a small group of healthy volunteers (typically 20-80 individuals) or, in cases where significant toxicity is expected, patients with the targeted disease, such as cancer or AIDS. The volunteers are tested for...
4.5K
Drug Discovery: Overview01:26

Drug Discovery: Overview

10.9K
Drug discovery is a multifaceted process involving extensive screening, testing, and optimization of lead compounds to identify potential new drugs for therapeutic use. It combines several approaches, including screening large numbers of natural products, chemical modification of known active molecules, identification of new drug targets, and rational design based on biological mechanisms and drug-receptor structure. These approaches are carried out in both academic research laboratories and...
10.9K
Drug Administration and Therapy Phases: Overview01:26

Drug Administration and Therapy Phases: Overview

1.1K
Drugs, the chemical agents used in diagnosing, treating, or preventing diseases, undergo a four-phase process of development: pharmaceutic, pharmacokinetics, pharmacodynamics, and therapeutic.
The pharmaceutical phase focuses on leveraging the physicochemical properties of the drug to design and manufacture an effective product. Variants include orally administered tablets or capsules, topical creams or ointments, and parenteral-delivery solutions or emulsions.
The pharmacokinetic phase...
1.1K
In Vitro Drug Release Testing: Overview, Development and Validation01:10

In Vitro Drug Release Testing: Overview, Development and Validation

269
In vitro dissolution and drug release tests assess how quickly and how much of a drug is released from its dosage form into an aqueous medium under standardized laboratory conditions. These tests are essential tools in pharmaceutical development and quality assurance, offering insight into the drug's performance before clinical use.During formulation development, dissolution testing identifies incomplete or inconsistent drug release issues. It also supports decisions on selecting the optimal...
269
Drug Regulation01:25

Drug Regulation

2.7K
Drug regulation encompasses the management of drug usage by evaluating its safety and efficacy through assessments conducted by regulatory authorities. Regrettably, the history of drug regulation is marred by several catastrophic events. One such incident is the Elixir Sulfanilamide tragedy, in which the toxic compound diethyl glycol was included in a sweet-tasting medication, leading to numerous fatalities. This event prompted the enactment of the Food, Drug, and Cosmetic Act in 1938. Under...
2.7K

También podría leer

Artículos Relacionados

Artículos vinculados a este trabajo por autores compartidos, revista y gráfico de citas.

Ordenar por
Same author

Preemptive Pediatric Kidney Transplantation and Social Determinants of Health: Individual-Level Versus Area-Based Measures.

Pediatric transplantation·2026
Same author

Beyond biological risk: socioeconomic vulnerability and adverse pediatric kidney transplant outcomes.

Pediatric nephrology (Berlin, Germany)·2026
Same author

Modeling internalizing symptoms in United States veterans using the Hierarchical Taxonomy of Psychopathology (HiTOP) framework: Gender invariance and longitudinal stability.

Journal of psychopathology and clinical science·2026
Same author

Impact of a diagnosis of 'low-grade dysplasia' in patients with Barrett's esophagus.

Diseases of the esophagus : official journal of the International Society for Diseases of the Esophagus·2026
Same author

Unraveling Emerging Data on Lipoprotein(a)-Driven Cardiovascular Disease via Multiomics: A Review.

Global heart·2026
Same author

Maternal sFlt-1/PlGF Ratio to Distinguish Pathological Fetal Growth Restriction From Constitutional Smallness: Systematic Review.

BJOG : an international journal of obstetrics and gynaecology·2026
Same journal

Unveiling the procoagulant state in Alzheimer's disease: A novel PET imaging strategy.

Alzheimer's & dementia : the journal of the Alzheimer's Association·2026
Same journal

Estimated labor market outcomes of people progressing from preclinical to early-stage Alzheimer's disease in the United States.

Alzheimer's & dementia : the journal of the Alzheimer's Association·2026
Same journal

Amyloid exacerbates tau and alpha-synuclein pathologies, behavioral impairments, and neuroinflammation in a mixed dementia model.

Alzheimer's & dementia : the journal of the Alzheimer's Association·2026
Same journal

Multimorbidity burden and patterns associated with DeepBrainNet-derived brain-age gap in dementia-free older adults: A community-based study.

Alzheimer's & dementia : the journal of the Alzheimer's Association·2026
Same journal

Reply to "Shifting the emphasis of brain health literacy from individuals to systems to reduce inequalities".

Alzheimer's & dementia : the journal of the Alzheimer's Association·2026
Same journal

Shifting the emphasis of brain health literacy from individuals to systems to reduce inequalities.

Alzheimer's & dementia : the journal of the Alzheimer's Association·2026
Ver todos los artículos relacionados
JoVE
x logofacebook logolinkedin logoyoutube logo
ACERCA DE JoVE
Visión GeneralLiderazgoBlogCentro de Ayuda JoVE
AUTORES
Proceso de PublicaciónConsejo EditorialAlcance y PolíticasRevisión por ParesPreguntas FrecuentesEnviar
BIBLIOTECARIOS
TestimoniosSuscripcionesAccesoRecursosConsejo Asesor de BibliotecasPreguntas Frecuentes
INVESTIGACIÓN
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchivo
EDUCACIÓN
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualCentro de Recursos para ProfesoresSitio de Profesores
Términos y Condiciones de Uso
Política de Privacidad
Políticas

Video Experimental Relacionado

Updated: Jan 7, 2026

Drug Repurposing Hypothesis Generation Using the "RE:fine Drugs" System
05:10

Drug Repurposing Hypothesis Generation Using the "RE:fine Drugs" System

Published on: December 11, 2016

10.1K

Desarrollo de Fármacos

David Watson1, Michael G Neam1, Mark Stafford1

  • 1Alzheimer's Research and Treatment Center, Wellington, FL, USA.

Alzheimer's & dementia : the journal of the Alzheimer's Association
|December 25, 2025
PubMed
Resumen
Este resumen es generado por máquina.

El tratamiento a largo plazo con lecanemab en la enfermedad de Alzheimer temprana (EA) demostró una reducción sostenida de amiloide y una ralentización de la progresión de la enfermedad. Los datos del mundo real mostraron una seguridad y eficacia comparables a los ensayos clínicos, y los pacientes informaron una mejor calidad de vida.

Palabras clave:
lecanemabenfermedad de Alzheimerensayos clínicosseguridadeficaciaresultados informados por el paciente

Más Videos Relacionados

In Vitro Three-Dimensional Sprouting Assay of Angiogenesis Using Mouse Embryonic Stem Cells for Vascular Disease Modeling and Drug Testing
08:04

In Vitro Three-Dimensional Sprouting Assay of Angiogenesis Using Mouse Embryonic Stem Cells for Vascular Disease Modeling and Drug Testing

Published on: May 11, 2021

3.3K
Developmental Toxicity Assay Based on Real-Time Monitoring of Fibroblast Growth Factor Signal Disruption in Human Induced Pluripotent Stem Cells
05:45

Developmental Toxicity Assay Based on Real-Time Monitoring of Fibroblast Growth Factor Signal Disruption in Human Induced Pluripotent Stem Cells

Published on: October 10, 2025

446

Videos de Experimentos Relacionados

Last Updated: Jan 7, 2026

Drug Repurposing Hypothesis Generation Using the "RE:fine Drugs" System
05:10

Drug Repurposing Hypothesis Generation Using the "RE:fine Drugs" System

Published on: December 11, 2016

10.1K
In Vitro Three-Dimensional Sprouting Assay of Angiogenesis Using Mouse Embryonic Stem Cells for Vascular Disease Modeling and Drug Testing
08:04

In Vitro Three-Dimensional Sprouting Assay of Angiogenesis Using Mouse Embryonic Stem Cells for Vascular Disease Modeling and Drug Testing

Published on: May 11, 2021

3.3K
Developmental Toxicity Assay Based on Real-Time Monitoring of Fibroblast Growth Factor Signal Disruption in Human Induced Pluripotent Stem Cells
05:45

Developmental Toxicity Assay Based on Real-Time Monitoring of Fibroblast Growth Factor Signal Disruption in Human Induced Pluripotent Stem Cells

Published on: October 10, 2025

446

Área de la Ciencia:

  • Neurología
  • Inmunoterapia
  • Investigación Clínica

Sus antecedentes:

  • Lecanemab, un anticuerpo monoclonal anti-amiloide, ha mostrado promesa en la enfermedad de Alzheimer temprana (EA).
  • Estudios previos indicaron una reducción de los marcadores de amiloide y una ralentización del deterioro cognitivo durante 18 meses.
  • Se observaron beneficios a largo plazo en estudios de extensión en abierto.

Objetivo del estudio:

  • Evaluar la seguridad y eficacia a largo plazo en el mundo real de lecanemab en pacientes con EA temprana.
  • Evaluar las perspectivas de los pacientes y cuidadores sobre la terapia con lecanemab.
  • Comparar los resultados del mundo real con los hallazgos de los ensayos clínicos.

Principales métodos:

  • Una serie de casos retrospectiva de un solo centro de 136 pacientes con EA temprana tratados con lecanemab.
  • Los datos recopilados incluyeron características basales, exposición al tratamiento, eficacia y seguridad.
  • Se evaluaron las experiencias de pacientes y cuidadores mediante una encuesta telefónica basada en los conceptos "Lo que más importa".

Principales resultados:

  • 42 pacientes recibieron lecanemab durante ≥3 años, con 14 recibiendo ≥5 años.
  • Se observó una reducción continua de amiloide y un retraso en el tiempo hasta la progresión durante 4 años.
  • No surgieron nuevas señales de seguridad; los eventos adversos, incluida la ARIA, fueron consistentes con los perfiles conocidos.
  • Los pacientes y los cuidadores informaron una estabilización de la enfermedad, una ralentización de la progresión y una mejora de la calidad de vida.

Conclusiones:

  • El tratamiento a largo plazo con lecanemab en un entorno del mundo real refleja la seguridad y eficacia de los ensayos clínicos.
  • La continuación de la terapia con lecanemab más allá de los ensayos apoya retrasos significativos en la progresión de la enfermedad.
  • La mayoría de los participantes del ensayo optaron por lecanemab a largo plazo, informando beneficios de extensión y mejora de la vida.